Table 2 The table displays for each included study the citation, interventions, and outcomes between single versus multiple PEDs

1

Chalouhi (2014) [11]

ASA + CPG; Poor non-responder to CPG: Prasugrel

Mostly anterior (91.3% versus 88.5%). Posterior circulation: 8.7% versus 11.5% (P = 0.6)

Mostly saccular. Fusiform and dissecting: 12.7% versus 23% (P = 0.9)

Mean size: 9.2 mm versus 11.8 mm (P = 0.02)

Dome ≥ 10 mm: 39% versus 52% (P = 0.2)

70.8% versus 29.2% patients

2 PEDs: 22.5%

3 PEDs: 3.9%

4 PEDs: 2.3%

5 PEDs: 0.7%

DAPT 6 months, followed by aspirin

Mean FU: 7.0 months versus 8.9 months (P = 0.01)

Complete or near-complete: 84% versus 87% (P = 0.8)

Retreatment: 6% versus 7.5% (P = 0.8)

Total complications: 5% versus 15% (P = 0.03)

Single PED: 3 hemorrhage and 4 ischemic

Multiple PEDs: 4 hemorrhage and 4 ischemic

In-stent stenosis ± 5%, respectively (P = 0.95)

2

Kabbasch (2016) [13]

ASA + CPG; Poor non-responder to CPG: Prasugrel

Anterior circulation: 90% versus 67%

Mostly saccular. Fusiform, dissecting, and blister: 20% versus 33% (P > 0.05)

Mean size: 4.9 ± 3.8 mm versus 8.3 mm ± 4.1 mm (P = 0.01)

Neck diameter: 4.8 ± 2.3 versus 6.9 ± 2.8 (P = 0.03)

51% versus 49% patients

No. of aneurysms treated with

1 PED: 53%

2 PEDs: 23%

3 PEDs: 21%

4 PEDs: 3%

DAPT 3 months, followed by ASA or CPG

Immediate FU with favorable occlusion (OKM C1-3 + D): 25% versus 44% (P = 0.3); complete occlusion (OKM D): 20% versus 28% (P = 0.2)

Midterm FU (median 7-months) with favorable occlusion: 70% versus 100% (P = 0.03); complete occlusion: 60% versus 93% (P = 0.05)

Retreatment: 15% versus 0%

Total complications (In-stent thrombosis): 5% versus 5.5%

3

Waqas (2019) [12]

ASA + CPG; Poor non-responder to CPG: Ticagrelor

Anterior circulation: 96.2% versus 91.7% (P = 0.08)

All saccular

Mean size: 7.9 ± 6.2 mm versus 10.4 ± 5.7 mm

74.5% versus 25.5% patients

No. of aneurysms treated with

1 PED: 74%

2 PEDs: 21%

3 PEDs: 3%

Not stated

Immediate FU: 60.9% versus 69.4% (P = 0.36)

Six-months FU: 67.1% versus 90% (P = 0.028)

Twelve-months FU: 74.7% versus 91.7% (P = 0.04)

Latest FU ≥ 12-months with

 < 90% occlusion: 13.3% versus 0%

 > 90% occlusion: 4.8% versus 8.3%

Complete occlusion 81.9% versus 91.7%)

(P = 0.057)

Retreatment: 16.2% versus 0% (P = 0.01)

Total complications: 5.6% versus 5.6%

Thromboembolic complication: 2.8% versus 2.8%

(TIA: 0.9% versus 0%; Infarct: 1.9% versus 2.8%) (P = 0.49)

SAH rates: 2.8% versus 2.8% (P = 0.49)

4

Link (2021) [1]

ASA + CPG; Poor non-responder to CPG: Ticagrelor

All anterior. Posterior circulation excluded

Saccular: 95.7% versus 91.5% (P = 0.323)

Fusiform, blister: 4.3% versus 8.5% (P = 0.323)

Mean size: 6.9 ± 4.8 mm versus 7.0 ± 4.6 mm (P = 0.360) (dome ≥ 10 mm: 19.5% versus 12.9%)

32.9% versus 67.1% patients

2 PEDs: 54.3%

3 PEDs: 12.9%

DAPT 6 months, followed by ASA

Six-months FU: 75.6% versus 92.9% (P = 0.017)

Twelve-months FU: 81.1% versus 98.4% (P = 0.014)

Longest FU: 92.5% versus 100% (P = 0.083)

Retreatment: 9.3% versus 3.2% (P = 0.212)

Total complications: 9.1% versus 10.9% (< 30 days: 6.5% versus 6.4% and > 30 days: 2.6% versus 4.5%)

Major < 30 days (1 large ICH and 1 delayed rupture of cavernous ICA): 2.2% versus 1.1% (P = 0.648)

Minor < 30 days (4 ischemic, 1 occipital ICH, 1 CCF, and 1 asymptomatic stent occlusion): 4.3% versus 5.3% (P = 0.800)

Major > 30 days (Thrombotic stroke): 0% versus 1.1% (P = 0.320)

Minor > 30 days (3 visual disturbances and 1 blindness in one eye after a year): 2.6% versus 3.4% (P = 0.821)

5

Vranic (2022) [7]

ASA + CPG

ASA + Prasugrel

ASA + Ticagrelor

CPG + Ticagrelor; Platelet function test: not performed

Anterior circulation: 96% versus 91.7% (P = 0.19)

All saccular

Mean size: P = 0.28 (dome diameter < 10 mm: 83.5% versus 77.1%; dome diameter ≥ 10 mm: 16.5% versus 22.9%)

Neck size: 4.08 ± 1.95 mm versus 3.83 ± 1.91 mm (P = 0.45)

83.9% versus 16.1% patients

2 PEDs: 12%

3 PEDs: 4%

DAPT at least 3 months (7.5 ± 4.2 versus 7.5 ± 2.5 months; P = 0.98)

Six-months FU: 70% versus 68.8%

6–12 months FU: 81.2% versus 83.4%

Latest FU (≥ 12 months): 83.6% versus 83.4%

(P = 0.65)

Retreatment: 8% versus 10.4% (P = 0.58)

Total complications: 8% versus 4.2% (P = 0.42)

Intracranial: 6% versus 4.2% (ICH: 2% versus 0%; Stroke: 0.8% versus 2.1%; TIA: 2% versus 0%; In-stent thrombosis: 0% versus 2.1%; Cranial neuropathy: 0.4% versus 0%)

Extracranial: 2% versus 0% (Groin hematoma: 0.8% versus 0%; Retroperitoneal hematoma: 1.2% versus 0%)